3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
58
Carcinoma, Hepatocellular
28
Breast Neoplasms
26
Small Cell Lung Carcinoma
20
Lung Neoplasms
20
Triple Negative Breast Neoplasms
18
Urinary Bladder Neoplasms
17
Neoplasms
16
Carcinoma, Transitional Cell
16
Neoplasm Metastasis
15
Melanoma
15
Colorectal Neoplasms
15
Uterine Cervical Neoplasms
11
Carcinoma, Renal Cell
10
Stomach Neoplasms
7
Recurrence
7
Head and Neck Neoplasms
7
Prostatic Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Mesothelioma, Malignant
5
Liver Neoplasms
5
Carcinoma, Squamous Cell
5
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Merkel Cell
4
Biliary Tract Neoplasms
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Thoracic Neoplasms
3
Interventions
Paclitaxel
4
Oxaliplatin
4
Cisplatin
4
Radiotherapy
3
Ocoxin
3
Folfox protocol
3
pembrolizumab
2
camrelizumab
2
apatinib
2
anlotinib
2
Sunitinib
2
Sorafenib
2
Imatinib Mesylate
2
Gemcitabine
2
Fluorouracil
2
Drug Therapy
2
Capecitabine
2
Bevacizumab
2
tislelizumab
1
sintilimab
1
regorafenib
1
pyrotinib
1
pemigatinib
1
genexol-PM
1
durvalumab
1
donafenib
1
copanlisib
1
atezolizumab
1
alectinib
1
Tretinoin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Digestive System Neoplasms
×
atezolizumab
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled